Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised Lendify in connection with new financing and redemption of bonds
Mandate

Vinge advised Lendify in connection with new financing and redemption of bonds

February 12, 2019 Banking and Finance

Lendify AB (“Lendify”), an online lender and one of Sweden’s most notable challengers in the banking sector, has secured new financing of up to SEK 1.000.000.000 from a large Swedish institution for the purpose of further financing its lending operations.

In connection with the new financing, Lendify’s two wholly owned subsidiaries, Lendify Sweden 1 AB and Lendify Sweden 2 AB, redeemed and de-listed their outstanding bonds from the Debt Securities list at the Nordic Derivatives Exchange.

Together with the management of the company, the institutional investor, the arranger and their legal advisors, Vinge has acted for Lendify in the structuring, documenting and execution of the transaction.

Vinge’s team mainly consisted of partner Albert Wållgren, associates Sebastian Frisk, Lionardo Ojeda and Axel Jansson (Banking and Finance) and partner Emma Stuart-Beck and associates Malin Haag and Caroline Krassén (Financial Services).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025